Letter to Shareholder

04

Business Overview

06

Persistent In Action

14

Financial Overview

16

Corporate Information

Statutory Reports

17

Management Discussion

and Analysis

24

Directors’ Report

42

Report on Corporate

Governance

Financial Statements

59

Consolidated

125 Standalone

190 Notice

Table of Contents:

Managing Director: Letter to Shareholder

Annual Report 2020-21

2

Managing Director Joint: Managing

Managing Director

Rajesh M. Agrawal ......................................Joint: Managing

Dear Shareholders,

Your Directors are pleased to present their Forty-Second Annual Report and Audited Financial Statements for the

Year ended 31 March 2021.

1.

Financial perFormance

(` in cr. except EPS)

particulars

Standalone

consolidated

Year ended 31 march

2021

2020

2021

2020

Revenue from operations

2,719

2,196

2,890

2,588

Other Income

104

184

26

92

Profit before Depreciation, Finance Costs and Tax expense

1,020

717

1,025

776

Profit after Tax

676

441

654

468

Total Comprehensive Income

674

439

647

473

Earning Per Share (EPS) (`) (Basic)

77.59

50.55

75.09

53.60

2.

perFormance review

The company achieved a growth of 12% in Consolidated

Revenue from Operations over the previous year, while

Consolidated Profit After Tax grew at 40% in spite of the

challenges faced due to pandemic. Exports contributed

around 71% of the business.

Company continues to be engaged in development,

manufacture and sale of generic and branded

pharmaceutical formulations.

3.

DiviDenD

At the Board meeting held on 3 November 2020, the

Board had declared an interim dividend of ` 9.50/-

(475%) per equity share in accordance with the Dividend

Policy. Total dividend payout was ` 82.90 cr. The Board

does not recommend any final dividend and accordingly

recommends interim dividend to be considered as final

dividend for FY 2021. The Dividend Distribution Policy

is placed on the website of the Company and its web-

link

is

http://www.ajantapharma.com/AdminData/

PolicyCodes/DividendPolicy.pdf

12%

consolidated revenue from

operations

(` cr.)

2,588

FY2020

2,890

FY2021

40%

Consolidated Profit after Tax

(` cr.)

468

FY2020

654

FY2021:

Managing Director;

Mr. Rajesh M. Agrawal, Joint: Managing Director;

Mr. Arvind K. Agrawal, Chief Financial Officer and

Mr. Gaurang Shah, Company Secretary are the

KMP of the Company as on the date of this report.

7.5. Board and Directors’ evaluation

As per provisions of the Act and Regulation 17(10)

of the Listing Regulations, the evaluation process

for the performance of the Board, its committees

and individual Directors was carried in accordance

with the manner specified by Board of Directors, as

suggested by the NRC. The evaluation was done

in accordance with the framework and criteria laid

down by the NRC. Further, at a separate meeting,

the Independent Directors evaluated performance

of Non-Independent Directors, Board as a whole

and of the

Letter of Appreciation from

the Governor of Maharashtra, for the wholehearted

support to the government and citizens in tackling the

numerous challenges posed by the COVID-19 pandemic

situation.

The CSR Committee reviews and monitors the CSR

projects and expenditure undertaken by the Company

on a regular basis and apprises the Board of the same.

CSR policy and CSR activities undertaken during the

year in accordance with Section 134 & 135 of the Act

read with Rule 8 of the Companies (Corporate Social

Responsibility Policy) Amendment Rules, 2021 and Rule

9 of the Companies (Accounts) Rules, 2014, is annexed

to this report as “annexure b”.

12. managemenT diSCuSSion and analySiS

A detailed review of the operations, performance and

future outlook, major events occurred during the year

as well as state of company’s affairs is given in the

Management Discussion and Analysis, which forms

part of this report.

13. rePorT on CorPoraTe goVernanCe

Report on Corporate Governance together with

certificate from the Practicing Company Secretaries

regarding compliance of conditions of Report on

Corporate Governance, is annexed and forms an integral

part of this report.

14. buSineSS reSPonSibiliTy rePorT

Business Responsibility Report (“BRR”) for FY 2021,

forms part of the Annual Report and the same has

been hosted on the Company’s website, which can

be

accessed

at

http://www.ajantapharma.com/

AnnualReports.aspx.

Any

Member

interested

in

obtaining a copy of BRR may write to the Company

Secretary.

9.

board CommiTTeeS

The Board currently has six committees, viz., Audit

Committee, Nomination and Remuneration Committee,

Corporate Social Responsibility Committee, Stakeholders

Relationship Committee, Risk Management Committee

and Executive Committee. All the recommendations

made by the Committees of Board including the Audit

Committee were accepted by the Board.

A detailed update on the committees, its composition,

number of Committee meetings held and attendance of

the directors at each meeting is provided in the Report

on Corporate Governance.

10. relaTed ParTy TranSaCTionS and PoliCy

All the Related Party transactions (“RPTs”) entered

into during the financial year were on an arm’s length

basis and in the ordinary course of business and in

accordance with the Company’s Policy on Related Party

Transactions.

Pursuant to Regulation 23(3) of the Listing Regulations

and Rule 6A of the Companies (Meetings of Board and

its Powers) Rules, 2014, the Audit Committee granted

omnibus approval to the transactions likely to be entered

into by the Company with related parties during the

year and are of repetitive nature. The Audit Committee

also reviewed all RPTs on quarterly basis. All the RPTs

affected during the year are disclosed in the notes to

Financial Statements.

There were no materially significant RPTs which could

have potential conflict with interest of the Company at

large.

During the year, the Company had not entered into

any transactions with related parties (save and except

transaction

with

company’s

subsidiaries),

which

could be considered as material in accordance with

the Company’s Policy on materiality of RPT or which

is required to be reported in Form AOC-2 in terms of

Section 134(3)(h) read with Section 188 of the Act and

Rule 8(2) of the Companies (Accounts) Rules, 2014.

11. CorPoraTe SoCial reSPonSibiliTy

During the year, Company continued Corporate Social

Responsibility

(“CSR”)

program

through

various

initiatives in the fields of COVID related assistance,

Education,

Community

Welfare,

Healthcare

and

Promoting Sports.

Directors’ Report:

Managing Director from subsidiaries;

Directors’ Report:

Managing Director

Chief Financial Officer

DIN: 00073673

Rajesh M. Agrawal

Gaurang Shah

Joint: Managing

Managing Director

Chairman of the Corporate Social Responsibility Committee

Mumbai, 30 April 2021

(g) Excess amount for set off, if any:

Sl No.

Particulars

Amount (in cr.)

(i)

Two percent of average net profit of the company as per section 135(5)

10.49

(ii)

Total amount spent for the financial Year

12.78

(iii)

Excess amount spent for the financial year [(ii)-(i)]

2.29

(iv)

Surplus arising out of the CSR projects or programmes or activities of the previous

financial years, if any

Nil

(v)

Amount available for set off in succeeding financial years [(iii)-(iv)]

2.29

Annexure - “B” to the Directors’ Report - Report on CSR:

letter of even date which is annexed as Annexure A and forms an integral part of this report.:

letter.

1.

The compliance of provisions of all laws, rules, regulations, standards applicable to Ajanta Pharma Limited (hereinafter

called ‘the Company’) is the responsibility of the management of the Company. Our examination was limited to the

verification of records and procedures on test check basis for the purpose of issue of the Secretarial Audit Report.

2.

Maintenance of secretarial and other records of applicable laws is the responsibility of the management of the Company.

Our responsibility is to issue Secretarial Audit Report, based on the audit of the relevant records maintained and furnished

to us by the Company, along with explanations where so required.

3.

We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the

correctness of the contents of the secretarial and other legal records, legal compliance mechanism and corporate conduct.

Further part of the verification was done on the basis of electronic data provided to us by the Company due to COVID-19

lockdown and on test check basis to ensure that correct facts as reflected in secretarial and other records produced to us.

We believe that the processes and practices we followed, provides a reasonable basis for our opinion for the purpose of

issue of the Secretarial Audit Report.

4.

We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.

5.

Wherever required, we have obtained the management representation about list of applicable laws, compliance of laws,

rules and regulations and major events during the audit period.

6.

The Secretarial Audit Report is neither an assurance as to the future viability of the Company nor of the efficacy or

effectiveness with which the management has conducted the affairs of the Company.

ANNExUrE A

Annexure - “C” to the Directors’ Report - Secretarial

Audit Report

For Alwyn D’Souza & Co.

Company Secretaries

Alwyn P D’Souza

FCS. 5559

Place: Mumbai

C.P. No. 5137

Date: 30 April 2021

UDIN: F005559C000217628:

Managing Director (“MD”). Agenda papers

with minutes of previous meeting, committee

meetings & meetings of subsidiary companies

and other information/proposals with detailed

notes/background information with applicable

All our Stakeholders including customers, vendors

and communities where we operate, are an integral

part of the business and we ensure fairness for every

one of them through transparency and accountability,

two basic tenets of corporate governance. Company

has guiding principles laid down through its Code of

Business Conduct duly adopted and adhered to by

directors and senior management personnel.

II.

Board of dIreCtors

a.

Composition and category of directors

The Board consists of an optimal combination

of Executive, Non-Executive and Independent

Directors (“IDs”) including an ID Woman Director.

Out of eight directors, three are Executive Promoter

Directors, one is Non-Executive Promoter Director

and four are IDs.

Board fulfils the criteria laid down under the

Board’s policy on diversity and has the vital mix

of skill, experience, independence and knowledge

to ensure its continued effectiveness. It has

combined experience portfolio of business acumen

& management, industry & sector knowledge,

international operations, marketing, finance, forex

Consistency

Integrity

trust

ethics

professionalism

Core values

Non-Executive Directors play a critical role

in setting up Board processes with their

independent judgment on issues of strategy,

performance,

resources,

standards

of

conduct, etc. They provide foresight, enhance

transparency and add value in decision making.

management, risk management, HR, Corporate

Governance and other attributes.

The Board strives to create long-term sustainable

growth to enhance value for all stakeholders. It

also sets out standards of corporate governance

and ensures compliance with laws and regulations

impacting

the

Company’s

business.

Board

guides corporate strategy, major plans of action,

risk policy, annual budgets and business plans,

performance parameters and monitors corporate

performance, puts in place various plans, policies

and practices for effectiveness of Company’s

governance practices and making changes as

needed. The Board also reviews and approves

strategic plan & business objectives.

Executive Directors and management provide

strategic

management

of

the

Company’s

businesses within the overall framework and

ensures business development and operational

excellence in accordance with the business

objectives.:

Managing Director

29/04/2000

4

Rajesh Mannalal Agrawal

00302467

Whole time Director

30/04/2013

5

Chandrakant Mohanlal Khetan

00234118

Director

20/10/2008

6

Prabhakar Ramchandra Dalal

00544948

Director

13/06/2014

7

Viswanathan Hariharan Kalpati

06563472

Director

30/04/2013

8

Dr. Anjana Grewal

06896404

Director

13/06/2014

Ensuring the eligibility for the appointment / continuity of every Director on the Board is the responsibility of the management

of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an

assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has

conducted the affairs of the Company.

For alwyn d’souza & Co.

Company Secretaries

alwyn d’souza

FCS No. 5559

Place: Mumbai

C. P. No. 5137

Date: 30 April 2021

udIn: F005559C000217650

Report on Corporate Governance:

Managing Director and Mr. Arvind Agrawal, Chief Financial Officer hereby certify for the financial year

ended 31 March 2021 that:

(a) We have reviewed IND AS financial statements and the cash flow statement for the year and that to the best of our knowledge

and belief:

(i)

these statements do not contain any materially untrue statement or omit any material fact or contain statements that

might be misleading;

(ii)

these statements together present a true and fair view of the company’s affairs and are in compliance with IND AS,

applicable laws and regulations.

(b) There are, to the best of our knowledge and belief, no transactions entered into by the company during the year which are

fraudulent, illegal or violative of the company’s code of conduct.

(c) We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated

the effectiveness of internal control systems of the company pertaining to financial reporting and we have disclosed to the

auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are

aware and the steps we have taken or propose to take to rectify these deficiencies.

(d) We have indicated to the auditors and the Audit committee

(i)

that there are no significant changes in internal control over financial reporting during the year;

(ii)

that there are no significant changes in accounting policies during the year; and

(iii) that there are no instances of significant fraud of which we have become aware.

For ajanta pharma limited

yogesh m. agrawal

Mumbai, 30 April 2021: Managing

Managing Director

Chief Financial Officer

Membership No. 111410

DIN: 00073673

Rajesh M. Agrawal

Gaurang Shah

Mumbai

Joint: Managing

Managing Director

Chief Financial Officer

Membership No. 111410

DIN: 00073673

Rajesh M. Agrawal

Gaurang Shah

Mumbai

Joint: Managing

Managing Director

Chief Financial Officer

Membership No. 111410

DIN: 00073673

Rajesh M. Agrawal

Gaurang Shah

Mumbai

Joint: Managing

Managing Director

Chief Financial Officer

Membership No. 111410

DIN: 00073673

Rajesh M. Agrawal

Gaurang Shah

Mumbai

Joint: Managing

Letter of Offer was made to all eligible shareholders.

The Company bought back 735,000 equity shares out of the shares that were tendered by eligible shareholders and

extinguished the equity shares bought back on 30 December 2020. The Company has utilised its Securities Premium

(` 1.64 Crore) and General Reserve (` 134.35 Crore) for the buyback of its equity shares. Total transaction cost of ` 0.78

Crore incurred towards buyback was offset from retained earnings. In accordance with Section 69 of the Companies Act

2013, The Company has created Capital Redemption Reserve of ` 0.15 Crore equal to the nominal value of the shares

bought back as an appropriation from the General Reserve.:

Managing Director

Rajesh M. Agrawal

Joint: Managing

Managing Director

A)

Following transactions were carried out with related parties:

` in Crore

Sr.

No.

Particulars

Category

Year Ended

31 March 2021

Year Ended

31 March 2020

1.

Compensation to Key Management & Others:

Short Term Employee Benefits

Madhusudan B. Agrawal

I

2.04

1.68

Yogesh M. Agrawal

I

9.55

8.38

Rajesh M. Agrawal

I

9.55

8.38

Arvind Agrawal

I

1.31

1.24

Gaurang Shah

I

0.64

0.54

Tanya Agrawal

III

0.07

0.06

Post-employment benefits

I

0.37

0.28

2.

Commission and Sitting Fees to Non-Executive Director

Mannalal B. Agrawal

I

0.05

0.04

Chandrakant M Khetan

I

0.09

0.08

K. H. Viswanathan

I

0.07

0.06

Prabhakar Dalal

I

0.07

0.06

Dr. Anjana Grewal

I

0.06

0.05

3.

Commission to Executive Director

Yogesh M. Agrawal

I

3.27

2.34

Rajesh M. Agrawal

I

3.27

2.34

4.

Dividend Paid

Key Management Personnel

I

0.03

0.04

Others

II

58.45

79.98

5.

Corporate Social Responsibility Expense

Seth Bhagwandas Agrawal Charitable Trust

II

0.45

0.34

Samta Purushottam Agrawal Memorial Foundation

II

6.06

9.40

Manisha Yogesh Agrawal Foundation

II

-

0.05

Smriti Rajesh Agrawal Foundation

II

-

0.05

Ajanta Foundation

II

0.06

-

6.

Contribution made to Group gratuity trust through

premium paid to LIC :

Premium paid

II

8.79

6.01

7.

Donation

Mamta and Madhusudan Agrawal Memorial Foundation

II

0.56

-

Manisha Yogesh Agrawal Foundation

II

0.10

-

Smriti Rajesh Agrawal Foundation

II

0.10

-

8.

Buyback of Equity Share

Yogesh M Agrawal, Trustee Yogesh Agrawal Trust

III

19.72

-

Rajesh M Agrawal, Trustee Rajesh Agrawal Trust

III

19.72

-

Ravi P Agrawal, Trustee Ravi Agrawal Trust

III

20.73

-

Aayush M Agrawal, Trustee Aayush Agrawal Trust

III

21.64

-

Ganga Exports being represented by Yogesh Agrawal,

Rajesh Agrawal & Ravi Agrawal

III

8.62

-

Notes to the Consolidated Financial Statements

for the year ended 31 March 2021:

Managing Director

Chief Financial Officer

Membership No. 111410

DIN: 00073673

Rajesh M. Agrawal

Gaurang Shah

Mumbai

Joint: Managing

Managing Director

Chief Financial Officer

Membership No. 111410

DIN: 00073673

Rajesh M. Agrawal

Gaurang Shah

Mumbai

Joint: Managing

Managing Director

Chief Financial Officer

Membership No. 111410

DIN: 00073673

Rajesh M. Agrawal

Gaurang Shah

Mumbai

Joint: Managing

Managing Director

Chief Financial Officer

Membership No. 111410

DIN: 00073673

Rajesh M. Agrawal

Gaurang Shah

Mumbai

Joint: Managing

Managing Director

Chief Financial Officer

Membership No. 111410

DIN: 00073673

Rajesh M. Agrawal

Gaurang Shah

Mumbai

Joint: Managing

Letter of Offer was made to all eligible shareholders. the Company

bought back 735,000 equity shares out of the shares that were tendered by eligible shareholders and extinguished the

equity shares bought back on 30 December 2020. The Company has utilised its Securities Premium (` 1.63 Crore) and

General Reserve (` 134.35 Crore) for the buyback of its equity shares. Total transaction cost of ` 0.78 Crore incurred towards

buyback and tax of ` 31.64 Crore was offset from retained earnings. In accordance with Section 69 of the Companies Act

2013, the Company has created Capital Redemption Reserve of ` 0.15 Crore equal to the nominal value of the shares

bought back as an appropriation from the General Reserve.

22.9 Equity shares extinguished on buy-back

The Company bought back 7,69,230 equity shares for an aggregate amount not exceeding of ` 100 Crore being 0.87%

of the total paid up equity share capital at ` 1,300 per equity share. The equity shares bought back were extinguished on

26 March 2019.

The Company bought back 7,35,000 equity shares for an aggregate amount not exceeding of ` 136 Crore being 0.84%

of the total paid up equity share capital at ` 1,850 per equity share. The equity shares bought back were extinguished on

30 December 2020.

Notes to the Standalone Financial Statements

as at 31 March 2021:

Managing Director

Rajesh M. Agrawal

Joint: Managing

Managing Director

B)

The following transactions were carried out with related parties:

` in Crore

Sr.

No

Particulars

Category

Year Ended

31 March 2021

Year Ended

31 March 2020

1.

Sale of Goods

APML

I

181.80

105.10

APPI

I

142.52

105.77

APMIL

I

0.45

4.23

APUI

I

614.43

434.96

APNL

I

-

(2.42)

2.

Dividend from Subsidiary Companies

APML

I

53.03

84.05

APPI

I

30.18

17.25

3.

Expenses Reimbursement to

APUI

I

3.23

5.81

APNL

I

0.50

0.60

4.

Compensation to Key Management and Others

Short Term Employee Benefits

Madhusudan B. Agrawal

II

2.04

1.68

Yogesh M. Agrawal

II

9.55

8.38

Rajesh M. Agrawal

II

9.55

8.38

Arvind Agrawal

II

1.31

1.24

Gaurang Shah

II

0.64

0.54

Tanya Agrawal

IV

0.07

0.06

Post-employment benefits

II

0.37

0.28

5.

Commission to executive director

Yogesh M. Agrawal

II

3.27

2.34

Rajesh M. Agrawal

II

3.27

2.34

6.

Commission and Sitting Fees to Non-Executive Director

Mannalal B. Agrawal

II

0.05

0.04

Chandrakant M. Khetan

II

0.09

0.08

K. H. Viswanathan

II

0.07

0.06

Prabhakar Dalal

II

0.07

0.06

Dr. Anjana Grewal

II

0.06

0.05

7.

Dividend Paid

Key Management Personnel

II

0.03

0.04

Others

III

58.45

79.98

8.

Commission from Subsidiary on Corporate Guarantee

APUI

I

0.46

0.22

9.

Corporate Social Responsibility Expense

Seth Bhagwandas Agrawal Charitable Trust

III

0.45

0.34

Samta Puroshattam Agrawal Memorial Foundation

III

6.06

9.40

Manisha Yogesh Agrawal Foundation

III

-

0.05

Smriti Rajesh Agrawal Foundation

III

-

0.05

Ajanta Foundation

III

0.06

-

Notes to the Standalone Financial Statements

for the year ended 31 March 2021:

Managing Director

Chief Financial Officer

Membership No. 111410

DIN: 00073673

Rajesh M. Agrawal

Gaurang Shah

Mumbai

Joint: Managing

letter

etc.

with

attested specimen signature of the duly

authorised signatory(ies) who are authorised

to vote, to the Scrutiniser by e-mail to

scrutinizer@ajantapharma.com with a copy

marked to helpdesk.evoting@cdslindia.com

•

Alternatively Non Individual shareholders are

required to send the relevant Board Resolution

/ Authority: letter etc. together with attested

specimen signature of the duly authorised

signatory who are authorised to vote, to the

Scrutiniser and to your Company at the email

address viz.; scrutinizer@ajantapharma.com

& investorgrievance@ajantapharma.com, if

they have voted from individual tab & not

uploaded same in the CDSL e-voting system

for the scrutiniser to verify the same.

22. Instructions for Shareholders attending the AGM

through VC/OAVM & e-voting during Meeting are as

under:

i.

The procedure for attending meeting & e-voting

on the day of the AGM is same as the instructions

mentioned above for remote e-voting.

ii.

The link for VC / OAVM to attend meeting will

be available where the EVSN of Company will

be displayed after successful login as per the

instructions mentioned above for remote e-voting.

iii.

Shareholders are encouraged to join the Meeting

through Laptops / IPads for better experience.

iv.

Further shareholders will be required to allow

camera and use internet with a good speed to

avoid any disturbance during the meeting.

v.

Please note that participants connecting from

mobile devices or tablets or through laptop

connecting via mobile hotspot may experience

audio/video loss due to fluctuation in their

respective network. It is therefore recommended

to use stable Wi-Fi or LAN connection to mitigate

any kind of aforesaid glitches.

Notice

letter of appreciation from

Governor of Maharashtra:

